BRD4 and cancer: Pancreatic cancer is a devastating malignancy characterized by a high fatality rate,[1] primarily attributed to the formidable challenges in early diagnosis.[2] BRD4, a member of the Bromodomain and Extraterminal (BET) protein family, is a promising target for anticancer drugs due to its involvement in organizing super‐enhancers (SEs) and regulating the expression of oncogenes.[3] Inhibiting BRD4 disrupts the communication between SEs and target promoters, leading to the specific repression of oncogenes that cancer cells depend on for survival and ultimately resulting in cell death.